Application of PAP PCR to monitor plasma cfDNA in advanced non-small cell lung can-cer

VernacularTitle:PAP动态监测血浆cfDNA在进展期非小细胞肺癌患者治疗中的应用
Author: Xiaoyan XU ¹ ; Zhao YAN ; Yumeng WANG ; Zhaoting MENG ; Jinliang CHEN ; Qingshan WANG ; Li LIN ; Yudong SU ; Shaofeng DING ; Lin ZHU ; Peng CHEN
Author Information

1. 天津医科大学肿瘤医院肺部肿瘤内科
Keywords: pyrophosphorolysis-activated polymerization(PAP); cfDNA; EGFR mutation; non-small cell lung cancer
From: Chinese Journal of Clinical Oncology 2018;45(2):83-87
CountryChina
Language:Chinese
Abstract: Objective:To explore the application of pyrophosphorolysis-activated polymerization(PAP)to monitor plasma cfDNA in ad-vanced non-small cell lung cancer(NSCLC).Methods:A total of 85 patients diagnosed with advanced NSCLC between March 2016 and June 2017 were enrolled in the present study. EGFR mutations in cfDNA extracted from the plasma were detected using PAP and ARMS-PCR technology.The concordance analysis of EGFR mutations involved plasma vs.tumor tissue and PAP vs.ARMS-PCR.Further-more,38 EGFR-positive patients were selected to monitor EGFR mutations with PAP.Results:No statistical differences in EGFR muta-tions were observed between plasma and tumor tissue(P=0.092),as well as PAP and ARMS-PCR(P=0.210).The detection rate of EGFR mutations in cfDNA was higher in the progressor than in the non-progressor(62.5% vs.21.3%,P<0.001).Conclusions:PAP can be used for detecting and monitoring EGFR mutations in cfDNA to predict disease progression.